GlassScriptPhysician profile
Bipin Pratachandra Desai
NPI 1669412599
$4,625.94
in general payments reported to CMS, 2019-2025
27 companies · $603 in 2025
The $603 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $311 · 2021: $483 · 2022: $900 · 2023: $941 · 2024: $947 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $767.04 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $625.86 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $598.05 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $537.35 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Kaleo, INC. | $253.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.03 | 2019-2025 | Elaprase |
| Pfizer INC. | $235.58 | 2019-2025 | |
| Cranial Technologies, INC | $203.62 | 2019-2025 | Doc Band |
| Neos Therapeutics, LP | $199.51 | 2019-2024 | Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $185.24 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Adlon Therapeutics L.P. | $142.75 | 2020-2021 | |
| Sanofi Pasteur INC. | $101.78 | 2019-2024 | |
| Alk-Abello, INC | $91.69 | 2024-2025 | Neffy, Grastek, Odactra |
| Collegium Pharmaceutical, INC. | $85.67 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $72.40 | 2021-2024 | Voxzogo 1.2mg |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.95 | 2023-2024 | Flumist Quadrivalent |
| Aimmune Therapeutics, INC. | $38.80 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $28.46 | 2025 | Bylvay |
| Shire North American Group INC | $28.29 | 2019 | |
| Sobi, INC | $19.08 | 2022 | |
| Cipher Pharmaceuticals US LLC | $18.53 | 2025 | Natroba, Spinosad |
| Actelion Pharmaceuticals US, INC. | $17.38 | 2025 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2025 | Zoryve |
| Owp Pharmaceuticals, INC. | $14.50 | 2024 | Subvenite |
| Aytu Biopharma, INC. | $14.15 | 2024 | Karbinal |
| Seqirus USA INC | $13.77 | 2022 | |
| Glaxosmithkline, LLC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.